Patents by Inventor Ian Thomas Huscroft

Ian Thomas Huscroft has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of GLYT1 transporters
    Patent number: 8163956
    Abstract: A compound of the formula (I): wherein R1, R2, R3, R4, Ar, A, n and m are defined herein, is disclosed as a GlyT1 inhibitor; pharmaceutical compositions containing the compound of the formula (I) are also disclosed as are their use in medicine, for example in the treatment of schizophrenia.
    Type: Grant
    Filed: June 13, 2006
    Date of Patent: April 24, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Wesley Peter Blackaby, Ian Thomas Huscroft, Linda Elizabeth Keown, Richard Thomas Lewis, Piotr Antoni Raubo, Leslie Joseph Street, Christopher George Thomson, Joanne Thomson
  • Therapeutic Agents
    Publication number: 20090286765
    Abstract: A compound of the formula (I): wherein R1, R2, R3, R4, Ar, A, n and m are defined herein, is disclosed as a GlyT1 inhibitor; pharmaceutical compositions containing the compound of the formula (I) are also disclosed as are their use in medicine, for example in the treatment of schizophrenia.
    Type: Application
    Filed: June 13, 2006
    Publication date: November 19, 2009
    Inventors: Wesley Peter Blackaby, Ian Thomas Huscroft, Linda Elizabeth Keown, Richard Thomas Lewis, Piotr Antoni Raubo, Leslie Joseph Street, Christopher George Thomson, Joanne Thomson
  • Tetrahydropyran compounds as tachykinin antagonists
    Patent number: 7393858
    Abstract: The present invention relates to compounds of formula (Ia) wherein A, B, n, m, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are defined herein, and pharmaceutically acceptable salts thereof; the compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migraine, emesis or postherpetic neuralgia.
    Type: Grant
    Filed: March 4, 2004
    Date of Patent: July 1, 2008
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Olivier Dirat, Jason Matthew Elliott, Ian Thomas Huscroft, Richard Alexander Jelley, Janusz Jozef Kulagowski, Piotr Antoni Raubo, Duncan Edward Shaw, Francine Sternfeld, Christopher John Swain
  • Sulfone derivatives as 5-HT7 receptor ligands
    Patent number: 7101892
    Abstract: The present invention relates to sulfone derivatives of formula (I): Ar—SO2—CR2R3-L-N(R1)2I wherein Ar, L, R1, R2 and R3 are as defined herein, and pharmaceutically acceptable salts and N-oxides thereof, useful in the treatment of a condition which is susceptible to treatment by modulation of 5-HT7 receptor activity, such as depression or a sleep disorder.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: September 5, 2006
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Sylvie Bourrain, Peter Alan Hunt, Ian Thomas Huscroft, Janusz Jozef Kulagowski, Clare London, Elizabeth Mary Naylor, Piotr Antoni Raubo, Eileen Mary Seward
  • Sulfone derivatives as 5-HT7 receptor ligands
    Publication number: 20040229864
    Abstract: The present invention relates to sulfone derivatives of formula (I):
    Type: Application
    Filed: May 14, 2004
    Publication date: November 18, 2004
    Inventors: Sylvie Bourrain, Peter Alan Hunt, Ian Thomas Huscroft, Janusz Jozef Kulagowski, Clare London, Elizabeth Mary Naylor, Piotr Antoni Raubo, Eileen Mary Seward
  • Azabicyclic ether derivatives and their use as therapeutic agents
    Patent number: 6727249
    Abstract: The present invention relates compounds of the formula (I): wherein X represents hydrogen, C1-4alkyl optionally substituted by a hydroxy, methoxy or benzyloxy group, or CO2(C1-2alkyl); Z is —CR9R10CH2— or —CH2CR9R10—; and R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migaine, emesis or postherpetic neuralgia.
    Type: Grant
    Filed: April 1, 2002
    Date of Patent: April 27, 2004
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Neil Roy Curtis, Ian Thomas Huscroft, Janusz Jozef Kulagowski, Piotr Antoni Raubo
  • Azabicyclic ether derivatives and their use as therapeutic agents
    Publication number: 20020193402
    Abstract: The present invention relates compounds of the formula (I): 1
    Type: Application
    Filed: April 1, 2002
    Publication date: December 19, 2002
    Inventors: Neil Roy Curtis, Janusz Jozef Kulagowski, Ian Thomas Huscroft, Piotr Antoni Raubo
  • Azabicyclic spiroether derivatives and their use as therapeutic agents
    Patent number: 6479486
    Abstract: The present invention relates compounds of the formula (I): wherein Z is —CR9R10CH2— or —CH2CR9R10—; and R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are of particular use in the treatment or prevention of depression, anxiety, pain, inflammation, migaine, emesis or postherpetic neuralgia.
    Type: Grant
    Filed: April 1, 2002
    Date of Patent: November 12, 2002
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Ian Thomas Huscroft, Janusz Jozef Kulagowski, Piotr Antoni Raubo
  • AZABICYCLIC SPIROETHER DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
    Publication number: 20020147207
    Abstract: The present invention relates compounds of the formula (I): 1
    Type: Application
    Filed: April 1, 2002
    Publication date: October 10, 2002
    Inventors: Ian Thomas Huscroft, Janusz Jozef Kulagowski, Piotr Antoni Raubo
  • Spiro-piperidine derivatives and their use as therapeutic agents
    Patent number: 6071928
    Abstract: The present invention relates to compounds of formula (I), wherein R is C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, which groups are optionally substituted by hydroxy, C.sub.1-4 alkoxy or NR.sup.a R.sup.b, where R.sup.a and R.sup.b each independently repesent hydrogen or C.sub.1-4 alkyl; or R is C.sub.1-4 alkyl substituted by Ar, and optionally further substituted by one or both of R.sup.4 and R.sup.5 ; R.sup.1, R.sup.2 and R.sup.3 represent a variety of substituents; R.sup.9 and R.sup.10 are each hydrogen, halogen, C.sub.1-6 alkyl, CH.sub.2 OR.sup.c, oxo, CO.sub.2 R.sup.a or CONR.sup.a R.sup.b where R.sup.c represents hydrogen, C.sub.1-6 alkyl or phenyl; X is --CH.sub.2, or --CH.sub.2 CH.sub.2 --; Y is --CH--, --CH.sub.2 --, --CH.sub.2 CH-- or --CH.sub.2 CH.sub.2 --, with the proviso that the sum total of carbon atoms in X+Y is 2 or 3; and when Y is --CH-- or --CH.sub.
    Type: Grant
    Filed: December 16, 1998
    Date of Patent: June 6, 2000
    Assignee: Merck Sharp & Dohme, Ltd.
    Inventors: Neil Roy Curtis, Ian Thomas Huscroft, Janusz Jozef Kulagowski, Christopher John Swain